Status: Recruiting
A First-in-Human Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of KUP-101A in Patients With Selected Advanced Solid Tumors
The purpose of this trial is to find the maximum tolerated and recommended Phase 2 dose of KUP-101A and to evaluate its safety and tolerability. Additionally, pharmacokinetics and pharmacodynamics will be assessed, and first data on KUP-101A's efficacy in patients with advanced solid tumors will be obtained.
Participants needed: 21
Trial details
Phase: Phase 1Age: 18+Biological sex: AllType: InterventionalSponsor: Kupando GmbHUpdated: May 20, 2026Locations: 2
Eligibility criteria
Histologically confirmed cancer with evidence of advanced disease for which no o... [+2]
Previous systemic treatment with TLR agonists, with the exception of TLR agonist... [+10]